Stock Taper
SCREENER COMPARE ANY 2 STOCKS
UPB
UPSTREAM BIO, INC.
NASDAQ
$6.69
▼ DOWN 1.47% (-0.10)

KEY STATISTICS

Market Cap$364.07 M
52w High$33.68
52w Low$5.85
Dividend Yield—
Frequency—
P/E-2.30
Volume445.48K
Shares Out.54.42M

COMPANY

LEADERSHIP

E. Rand Sutherland
CHIEF EXECUTIVE
E. Rand Sutherland

COMPENSATION 2026

Salary$650,000
Stock Awards$0
Incentive Plan Pay$341,250
All Other Comp.$10,500
Total$4,302,100

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 11, 2024
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
75

PRICE TARGET

Target High$25.00
Target Low$15.00
Target Median$20.00
Target Consensus$20.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$522.50K
NOV
4
WED

PRICE

$6.69 ▼ DOWN 1.47% (−$0.10)
$6.60$6.67$6.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM6.69

About Upstream Bio, Inc.

https://upstreambio.com ↗

Upstream Bio, Inc., a 2021-founded clinical-stage biotech in Waltham, MA, develops treatments for inflammatory respiratory diseases, including verekitug, a monoclonal antibody targeting the thymic stromal lymphopoietin receptor for conditions like...

INDUSTRY

Biotechnology

A PRODUCT UPSTREAM BIO, INC. IS KNOWN FOR

Verekitug
Verekitug

Verekitug, a clinical-stage monoclonal antibody targeting the TSLP receptor, is in Phase 2 trials for severe asthma, CRSwNP, and COPD, serving as Upstream Bio's lead product candidate.

COMPETITORS

COMPETITOR
AMGN COMPARE
AZN COMPARE
GSK COMPARE
REGN COMPARE
SNY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
94
LISTED HERE
16
RANKED BY POSITION SIZE
VTI
0.00% · 1.4M
XSU.TO
0.01% · 909.0K
SCHA
0.00% · 160.2K
DFAS
0.01% · 150.5K
FFSM
0.06% · 102.5K
R2US.L
0.01% · 88.0K
AVSC
0.02% · 80.5K
SBIO
0.19% · 67.3K
SURI
0.48% · 62.1K
BBC
0.67% · 51.4K
PRFZ
0.01% · 33.6K
XRSU.L
0.01% · 31.0K
RSSL
0.01% · 16.7K
BIB
0.01% · 1.9K
USFMDN.MX
0.00% · 93
RESM
0.01% · 71

INSTITUTIONAL OWNERSHIP

SHARES OWNED
68.99%
HOLDERS
177
TOP 12 OF 177 · RANKED BY POSITION SIZE
Fmr LLC
8.1M sh · $72.91M
Orbimed Advisors LLC
5.7M sh · $107.1M
Blackrock, Inc.
3.4M sh · $30.34M
Decheng Capital LLC
3.3M sh · $61.8M
Norges Bank
2.9M sh · $78.26M
Enavate Sciences Gp, LLC
2.5M sh · $22.14M
Vanguard Group Inc
2.4M sh · $45.94M
Bain Capital Life Sciences Investors, LLC
2.4M sh · $45.89M
Tcg Crossover Management, LLC
2.1M sh · $39.82M
Ubs Group AG
1.8M sh · $49.04M
Janus Henderson Group Plc
1.5M sh · $41.42M
Altshuler Shaham Ltd
1.4M sh · $26.65M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Deykin Aaron
Sale · 895 shares
2026-06-16
★
OFFICER: GENERAL COUNSEL
Ambrose Allison
Sale · 477 shares
2026-06-16
★
OFFICER: CFO AND COO
GRAY MICHAEL
Sale · 853 shares
2026-06-16
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Sutherland Everett Rand
Sale · 2.1K shares
2026-06-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 1
BUY 1
OUTPERFORM 1
IN LINE 1
4 GRADES IN THE LAST 12 MONTHS
JP Morgan NEUTRAL Truist Securities BUY Mizuho OUTPERFORM Evercore ISI Group IN LINE

SECTORS PEERS

PEERPRICE
SYRE$90.36COMPARE
RLAY$18.77COMPARE
AMLX$34.74COMPARE
PHVS$35.32COMPARE
ZBIO$31.27COMPARE
NTLA$12.87COMPARE
SNDX$19.54COMPARE
NVAX$9.26COMPARE